Daily 800 mg versus 600 mg Efavirenz for HIV Patients Treating Tuberculosis with a Rifampicin-Based Regimen: An Open Label Randomized Controlled Trial

<div>Observed adverse events in 123 participants using EFV and RIF regimens according to trial arm (800mg EFV-regimen or 600mg EFV-regimen).</div>

BioMed Research International

fig5

Figure 5

Figure 5: Daily 800 mg versus 600 mg Efavirenz for HIV Patients Treating Tuberculosis with a Rifampicin-Based Regimen: An Open Label Randomized Controlled Trial 

Figure 5 | Daily 800 mg versus 600 mg Efavirenz for HIV Patients Treating Tuberculosis with a Rifampicin-Based Regimen: An Open Label Randomized Controlled Trial 